Description

HLF1-11, a human lactoferrin-derived peptide, is a broad spectrum antimicrobial agent. HLF1-11 inhibits human MPO activity. HLF1-11 also directs GM-CSF-driven monocyte differentiation toward macrophages, and enhances immune responses[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–COVID-19-immunoregulation–C56H95N25O14S—-[1]Marty Wulferink, et al. The Peptide hLF1-11 as Broad Spectrum Antmicrobial Prophylaxis in HSCT Patients. Blood (2005) 106 (11): 3241. |[2]van der Does AM, et al. Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrob Agents Chemother. 2010 Feb;54(2):811-6. |[3]van der Does AM, et al. The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity. J Immunol. 2012 May 15;188(10):5012-9. |[4]Faber C, et al. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob Agents Chemother. 2005 Jun;49(6):2438-44. |[5]Lupetti A, et al. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother. 2000 Dec;44(12):3257-63.|[6]upetti A, et al. Human lactoferrin-derived peptide’s antifungal activities against disseminated Candida albicans infection. J Infect Dis. 2007 Nov 1;196(9):1416-24. –183623-03-2–1374.58–99.91–N=C(NCCC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@H](C(N[C@H](C(O)=O)C)=O)CS)=O)=O)CCC(N)=O)=O)C(C)C)=O)CO)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)NC(CN)=O)N–Infection–DMSO : ≥ 100 mg/mL–Bacterial;Fungal;Glutathione Peroxidase—-Anti-infection;Apoptosis;Metabolic Enzyme/Protease–Peptides